ABO-504
Stargardt Disease
PreclinicalActive
Key Facts
About Abeona Therapeutics
Abeona Therapeutics is dedicated to delivering transformative cell and gene therapies for patients with severe rare diseases. The company has achieved a significant milestone with the commercial launch of ZEVASKYN® and maintains a diverse pipeline spanning preclinical to Phase 1/2 development, primarily targeting inherited retinal diseases and neurological conditions. Its strategy is supported by in-house manufacturing capabilities at The Elisa Linton Center for Rare Disease Therapies and key partnerships with Ultragenyx and Taysha Gene Therapies.
View full company profileTherapeutic Areas
Other Stargardt Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Tinlarebant (LBS-008) | Belite Bio | Phase 3 |
| OCU410ST (AAV5-hRORA) | Ocugen | Phase 2/3 |